Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Inhibitors of the HSP90 molecular chaperone: current status.

Sharp S, Workman P.

Adv Cancer Res. 2006;95:323-48. Review.

PMID:
16860662
2.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

3.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
4.

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Donnelly A, Blagg BS.

Curr Med Chem. 2008;15(26):2702-17. Review.

5.

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G.

J Mol Med (Berl). 2006 Aug;84(8):635-46. Epub 2006 Jun 2. Review.

PMID:
16741751
6.
7.

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.

Ann N Y Acad Sci. 2006 Nov;1086:21-34. Review.

PMID:
17185503
9.

Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.

Neckers L.

Curr Top Med Chem. 2006;6(11):1163-71. Review.

PMID:
16842153
10.

Geldanamycin and its derivatives as Hsp90 inhibitors.

Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G, Wozniak F.

Front Biosci (Landmark Ed). 2012 Jun 1;17:2269-77. Review.

PMID:
22652777
11.

Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

Kim T, Keum G, Pae AN.

Expert Opin Ther Pat. 2013 Aug;23(8):919-43. doi: 10.1517/13543776.2013.780597. Epub 2013 May 4. Review.

PMID:
23641970
12.

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P.

Expert Opin Biol Ther. 2002 Jan;2(1):3-24. Review.

PMID:
11772336
13.

[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].

Miyata Y.

Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. Review. Japanese.

PMID:
12617036
14.

Overview: translating Hsp90 biology into Hsp90 drugs.

Workman P.

Curr Cancer Drug Targets. 2003 Oct;3(5):297-300. Review.

PMID:
14529382
15.

[Heat shock protein 90: novel target for cancer therapy].

Chen Y, Ding J.

Ai Zheng. 2004 Aug;23(8):968-74. Review. Chinese.

PMID:
15301726
16.

Hsp90: an emerging target for breast cancer therapy.

Beliakoff J, Whitesell L.

Anticancer Drugs. 2004 Aug;15(7):651-62. Review.

PMID:
15269596
17.

Geldanamycin and its anti-cancer activities.

Fukuyo Y, Hunt CR, Horikoshi N.

Cancer Lett. 2010 Apr 1;290(1):24-35. doi: 10.1016/j.canlet.2009.07.010. Epub 2009 Oct 21. Review.

PMID:
19850405
18.

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

Hanson BE, Vesole DH.

Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83. doi: 10.1517/13543780903158934. Review.

PMID:
19642950
19.

The Hsp90 chaperone complex as a novel target for cancer therapy.

Goetz MP, Toft DO, Ames MM, Erlichman C.

Ann Oncol. 2003 Aug;14(8):1169-76. Review.

PMID:
12881371
20.

Heat shock protein 90 inhibition in lung cancer.

Shimamura T, Shapiro GI.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. doi: 10.1097/JTO.0b013e318174ea3a. Review.

Supplemental Content

Support Center